Next-Generation Sequencing and FFPE: Unlocking Genomic Insights

In recent years, advancements in genomic research have accelerated at an astonishing pace, with next-generation sequencing (NGS) playing a central role in this revolution. For researchers and clinicians working with preserved tissue samples, the combination of NGS and formalin-fixed paraffin-embedded (FFPE) tissue has opened new doors in cancer research, disease diagnostics, and therapeutic development. This intersection of FFPE preservation and modern sequencing technologies demonstrates how next-generation sequencing works to extract meaningful genomic data from archived samples and unlocks deeper insights into human biology.

With the widespread availability of formalin-fixed paraffin-embedded (FFPE) tissue samples, researchers and pathologists now have a practical and powerful tool for applying next-generation sequencing to the study of the tumor microenvironment and its immune-specific counterpart, the tumor immune microenvironment. In this blog, we explore how FFPE samples support next-generation DNA sequencing workflows to reveal the spatial, cellular, and molecular dynamics of cancer biology, while also addressing common questions such as how much next-generation sequencing costs and how sequencing strategies vary by research goal. Let’s explore the evolving intersection of next-generation DNA sequencing, FFPE samples, and how they are helping scientists unlock the secrets of human biology.

What is Next-Generation Sequencing?

Next-generation sequencing refers to a suite of technologies that enable high-throughput analysis of DNA and RNA. At its core, this approach is designed to generate massive volumes of genetic data in parallel, unlike traditional Sanger sequencing, which sequences DNA one fragment at a time. Next-generation DNA sequencing can process millions of fragments simultaneously, dramatically reducing turnaround time while increasing analytical depth. This allows researchers to gain a comprehensive view of genetic material more efficiently, accurately, and affordably than ever before.

The technology has made it possible to perform complex tasks like whole genome sequencing—analyzing an organism’s entire DNA sequence in one go—and transcriptomic analysis, which reveals how genes are expressed across different tissues and conditions. These capabilities have reshaped how scientists study disease mechanisms, genetic variation, and molecular signaling pathways.

In practical terms, NGS has become essential in fields like oncology, pathology, infectious disease, and pharmacogenomics. Its clinical and research value lies not only in scale but in its ability to extract actionable insights from diverse types, and its power increases exponentially when paired with the vast repositories of FFPE tissue samples collected in clinical settings.

How Does Next-Generation Sequencing Work?

Next-generation sequencing (NGS) reads DNA by breaking it into millions of tiny fragments and sequencing them all at the same time. These fragments are amplified, read base by base, and then digitally reassembled using powerful software to map the full genetic sequence. The result is fast, highly accurate data that reveals genetic variations, mutations, and patterns that would be difficult or impossible to detect with older sequencing methods.

How Much Does Next-Generation Sequencing Cost?

Leveraging existing FFPE samples for genomic studies eliminated the need for fresh tissue, reducing both costs and logistical barriers. This approach accelerates research timelines and enables studies to use historical cohorts without additional patient recruitment. For example, targeted gene panels are the most affordable option, often costing a few hundred dollars per sample. Whole exome sequencing (WES), which analyzes all protein-coding regions, typically costs more due to higher data output and analysis requirements, ranging from roughly $500 to $1,500 per sample depending on coverage depth and bioinformatics support. Whole genome sequencing (WGS) is the most comprehensive and expensive option, usually ranging from about $1,500 to $4,000 or more per sample, though costs have steadily declined as technology improves.

The Role of FFPE Tissue in Genomic Research

Formalin-fixed paraffin-embedded (FFPE) tissue is the standard method for long-term preservation of clinical biopsy and surgical specimens. Its widespread adoption in hospitals and pathology labs has resulted in vast archives of well-documented patient samples, making FFPE samples incredibly valuable for retrospective studies, allowing researchers to correlate genomic data with historical clinical outcomes, including treatment response, disease progression, and survival data.

However, extracting high-quality nucleic acids from FFPE tissue presents challenges due to the chemical cross-linking and degradation that occur during the fixation process. These artifacts can affect fragment length and sequence quality if not properly addressed. Fortunately, innovations in NGS library preparation, bioinformatics, and tissue processing have made it increasingly feasible to extract reliable DNA and RNA for next-generation sequencing. This has made FFPE-compatible NGS a game-changer in both research and clinical environments.

FFPE and Whole Genome Sequencing: A Retrospective Powerhouse

Whole genome sequencing provides an unbiased, comprehensive view of the entire genome, capturing both coding and non-coding regions. This breadth allows researchers to examine genetic variation beyond known disease-associated genes, offering a more complete picture of genomic architecture. When paired with FFPE samples, it enables researchers to:

Identify mutations and structural variations that may have contributed to disease progression.
Study rare genetic disorders using archival tissue, particularly when fresh or prospective samples are unavailable.
Examine tumor heterogeneity over time by analyzing serial biopsies, allowing genomic changes to be tracked across disease progression or treatment response.
The ability to perform whole-genome sequencing on FFPE samples is especially valuable in cancer genomics. It helps pathologists and oncologists detect actionable mutations, resistance mechanisms, and hereditary cancer risk, while also providing retrospective context that links genomic alterations to prior therapies and outcomes. These insights that directly influence patient care and treatment decisions, bridging archival research with modern precision medicine.

Transcriptomic Analysis in FFPE Samples: Measuring Gene Expression

Transcriptomic analysis refers to the study of RNA transcripts that the genome produces under specific conditions. It provides essential insights into which genes are active or suppressed, and the extent to which they are expressed. In recent years, next-generation sequencing (NGS) has made transcriptomic analysis in FFPE samples more accessible and reliable. This advancement enables researchers to combine historical FFPE tissue archives with modern sequencing technologies, expanding the scope of retrospective studies and deepening molecular insights.

Researchers now frequently use NGS-based transcriptomic analysis to characterize tumor subtypes through detailed gene expression profiling. This approach also helps identify both prognostic and predictive biomarkers, which are critical for understanding disease progression and guiding treatment strategies. By analyzing transcriptomic data, primary antibodies, and secondary antibodies from FFPE samples, scientists can detect subtle differences in gene expression that may influence therapy selection and patient outcomes. Additionally, transcriptomic data derived from FFPE samples contribute significantly to unraveling the molecular mechanisms underlying various diseases. These analyses support integrative studies that link genomic, transcriptomic, and clinical data to provide a more complete understanding of disease biology.

While working with RNA from FFPE tissues can be technically challenging due to degradation during the fixation process, modern extraction protocols and advanced library preparation kits have significantly improved RNA sequencing outcomes. As a result, archived FFPE samples can now be used in retrospective studies to uncover gene expression patterns that correlate with patient responses or clinical outcomes. This enables researchers to revisit historical cohorts and generate novel insights without the need to collect fresh tissue.

Why FFPE-NGS Integration Matters

The integration of FFPE tissue with next-generation sequencing technologies bridges the gap between clinical practice and molecular research. By combining archival tissue resources with modern high-throughput sequencing, researchers and clinicians gain access to data previously unavailable, expanding the depth and breadth of genomic insights. This integration also allows researchers to plan studies with a clear understanding of resource requirements, including considerations of how much next-generation sequencing costs for different platforms and workflows, helping institutions balance budgets with research goals. This synergy provides several key advantages:

1. Retrospective Research Potential

FFPE tissue banks around the world house millions of preserved samples. When these samples are analyzed with NGS, researchers can explore disease evolution over time and validate findings across diverse patient cohorts, making these archives a treasure trove for genomic discovery and validation.

2. Improved Diagnostic Accuracy

Next-generation DNA sequencing of FFPE samples allows clinicians to detect genetic mutations with a high degree of sensitivity and specificity, even from small or degraded samples. This improved resolution can help uncover low-frequency variants and subtle changes that might otherwise be missed, enhancing diagnostic confidence.

3. Personalized Medicine

NGS enables the tailoring of therapies based on an individual’s genomic profile. FFPE-derived NGS data support precision oncology and other fields where targeted therapies are rapidly evolving.

Overcoming Challenges in FFPE-NGS

Despite the remarkable benefits of combining FFPE samples with next-generation sequencing, several obstacles remain. One of the most common issues is the degradation of nucleic acids; the formalin fixation process tends to fragment and chemically modify the amount of usable material for sequencing. These chemical modifications can also introduce sequencing artifacts if not properly accounted for, underscoring the importance of careful sample preparation and quality control. Furthermore, the complex nature of FFPE-derived sequences requires sophisticated bioinformatics tools to process and interpret the data effectively, enabling researchers to distinguish genuine variants from technical noise arising from cross-linked and fragmented nucleic acids.

To address these challenges, Superior BioDiagnostics applies optimized extraction methods and uses cutting-edge sequencing platforms specifically tailored for FFPE samples. Their protocols are designed to maximize nucleic acid recovery and maintain the integrity of both DNA and RNA, even from highly degraded tissues. With a team of skilled experts and a focus on quality at every stage, Superior BioDiagnostics is equipped to produce high-quality genomic data even from degraded or difficult specimens, ensuring reliable results that support both research discovery and clinical decision-making.

Applications of FFPE-Enabled Next Generation

The integration of FFPE samples with next-generation DNA sequencing is revolutionizing research across several fields. In cancer genomics, for example, scientists can now profile tumors by identifying somatic mutations, gene fusions, and copy number variations directly from archived tissue. In neurology, researchers study the molecular underpinnings of neurodegenerative diseases using historical brain specimens, allowing comparisons across decades of collected samples and facilitating the discovery of novel biomarkers.

Immunology also benefits from this approach, with scientists now able to explore gene expression patterns within the immune system using preserved tissues. By integrating transcriptomic and genomic data, researchers can map immune cell activity and signaling pathways with greater precision than ever before. Even in infectious disease research, FFPE samples allow for the identification of pathogen genomes in older tissue collections, helping trace historical outbreaks and informing epidemiological models for emerging pathogens.

Across all of these disciplines, transcriptomic analysis and whole genome sequencing of FFPE tissue are delivering unprecedented insight into the biology, development, and potential treatment of a wide range of conditions. The combination of archival FFPE samples with advanced NGS technologies has made previously inaccessible data available, accelerating discoveries in personalized medicine, biomarker validation, and translational research.

The Future of FFPE and NGS

As next-generation sequencing technologies continue to evolve, so do the possibilities for extracting meaningful, actionable data from challenging sample types like FFPE. Emerging techniques in library preparation and molecular barcoding are further increasing the reliability of data derived from archival tissues. Advances in extraction chemistries, the increasing fidelity of sequencing instruments, and powerful bioinformatics platforms have transformed FFPE tissue from a problematic material into a valuable resource.

For institutions like hospitals, research universities, and biotech companies, this evolution means that massive archives of preserved tissue samples are no longer static collections—they’re dynamic reservoirs of untapped genomic information. Unlocking this potential could lead to breakthroughs in diagnostics, drug development, personalized therapies, and our broader understanding of human health.

Maximize the Potential of Your FFPE Samples with Superior BioDiagnostics

At Superior BioDiagnostics, we combine clinical precision with research-driven innovation to transform both malignant and normal FFPE tissue samples into actionable genomic insights. Our biobank offers ethically sourced, ISBER-compliant FFPE samples, carefully curated for both quality and diversity, so researchers can access the specimens they need for robust studies. Whether you’re working with archived cancer specimens or healthy tissue controls, our proprietary products and optimized workflows are designed to ensure high-quality nucleic acid extraction and sequencing performance, even from the most degraded samples.

Our team brings deep expertise in next-generation sequencing, including transcriptomic analysis and whole-genome sequencing, and supports a broad range of applications, from retrospective studies to clinical biomarker discovery and validation. Superior BioDiagnostics empowers you to maximize value from your FFPE samples. By partnering with a trusted U.S.-based biobank, you gain access to reliable specimens and comprehensive metadata that enhance the reproducibility and impact of your research. Are you ready to unlock the full potential of your FFPE samples with next-generation sequencing? Contact Superior BioDiagnostics today and discover how our team can support your next genomic research breakthrough.